The “BB Dose”: a Unither innovation that guarantees more safety with the infant

serum-physiologique-biolane PNG

Unither Pharmaceuticals is the world leader in the production of sterile single-unit dosage forms using the Blow-Fill-Seal (BFS) technology.

Since 1993, Unither Pharmaceuticals has been conducting various studies to better meet laboratories needs and thus facilitate patient medication intake. The new system brought by Unither, called “nose project”, does not damage the baby’s nose.

One of the studies conducted by UC/Consultants focuses on the use of physiological serum on infants. We found that mothers perceive the “physiological serum” as a neutral water, with a neutral pH, which does not necessarily contain antiseptic; Or a liquid such as blood. As for its use, the mothers always operate with a defined ritual, which shows their involvement around the product. Their expectations are very strong: the mothers are paying attention to every detail. The fear of hurting the baby with the (badly cut) tip and the risk of injury inside the nose remain present when using physiological serum.

Recently, Unither Pharmaceuticals partnered with Biolane to developed a single-unit dose featuring a more rounded tip that fits perfectly with babys’ nostrils. The “BB dose” guarantees a greater safety of the gesture of the mother with the infant. And avoids to skin him during the use of the physiological serum.

In addition to that, BFS technology enables the manufacture of preservative-free single-unit doses. Preservatives are recognized as potentially harmful to the sensitive mucosae of the eyes, nose, and lungs, so this is an enormous benefit to sensitive patients such as infants. Another advantage of unit-doses is that they are portable and easy to use individually, excellent properties for today’s active lifestyles.